TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05116800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
Study: NCT05381246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, and pericardial meridian 6th point (PC6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected three different points will also be applied to the other extremity, a total of 18 minutes of compression will be applied to each point, provided that it is three minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: In the reiki group, the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
Study: NCT06528275

Intervention type: OTHER
Intervention: Health promotion intervention
Description: Health promotion intervention with activites linked to nutrition, and distribution of baskets of fresh fruits and vegetables
Study: NCT05355350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin / Tazobactam Injection
Description: 4.5 grams QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 gram TID
Study: NCT06501287

Intervention type: DIAGNOSTIC_TEST
Intervention: Postprandial triglyceride
Description: impact of postprandial triglyceride level on coronary atherosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Postprandial triglyceride
Description: impact of postprandial triglyceride level on coronary atherosclerosis
Study: NCT06131164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercise Group
Description: The subjects in this group will perform Diaphragmatic Breathing Exercise Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Extension Exercise Group
Description: The subjects in this group will perform Thoracic Extension Exercise Group
Study: NCT06083922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1, 8 and 15, Cycles 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1, 8 and 15, Cycles 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+
Study: NCT06501287

Intervention type: DIAGNOSTIC_TEST
Intervention: Postprandial triglyceride
Description: impact of postprandial triglyceride level on coronary atherosclerosis
Study: NCT04989101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nigella
Description: The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
Study: NCT06418139

Intervention type: OTHER
Intervention: No intervention
Description: No intervention added by the study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention added by the study
Study: NCT04798651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cerebro-spinal fluid
Description: 1 ml of cerebro-spinal fluid
Study: NCT03917407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DUR-928 (Moderate AH)
Description: A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DUR-928 (Severe AH)
Description: Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study.
Study: NCT05174182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A novel treatment approach
Description: A novel treatment approach, as described before.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care, as described before.
Study: NCT05291169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omeza® OCM™
Description: Omeza® OCM™ is a wound care matrix comprised of coldwater fish peptides (device) and cod liver oil (drug).~OCM™is supplied in a sterile single use vial.
Study: NCT06110169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial Direct Current Stimulation (Anodal tDCS)
Description: Battery driven tDCS will be applied at 2 mA intensity to the dorsolateral prefrontal cortex and primary motor cortex for 20 minutes.
Study: NCT06344845

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PBB3 PET/CT scan
Description: Patients with suspected neurodegeneration underwent PET/CT scan after injection of 370MBq (10 mCi)18F-FDG to observe for TAU deposition.
Study: NCT06110169

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Participants will receive 20 minutes of sham anodal tDCS
Study: NCT06143930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening ex with BFR training
Description: Therapeutic strengthening training with blood flow restriction of trained limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening ex
Description: Therapeutic strengthening training program for lower extremities.
Study: NCT05429736

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor Skill Training (MST)
Description: During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Skill Training (MST)
Description: During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulation (TSS)
Description: TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.
Study: NCT06317129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic gastric restriction and biliodigestive diversion
Description: The BariTon™ is endoscopically implanted.
Study: NCT06087627

Intervention type: DRUG
Intervention: Dupilumab SAR231893 (REGN668)
Description: Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
Study: NCT04909983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DPLX-PT1
Description: A polymer skin patch for occlusional therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Standard of care
Study: NCT06193551

Intervention type: DEVICE
Group type: OTHER
Intervention: Ovitex LPR
Description: Robotic assisted laparoscopic repair of hiatal hernia using permanent sutures with Ovitex mesh as reinforcement.
Study: NCT05707039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open kinetic chain exercises
Description: In open chain exercises extremities are free to move and there is no weight bearing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises
Description: In closed kinetic chain exercises extremities are fixed and weight bearing is done.
Study: NCT05511077

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.
Study: NCT05520892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin
Description: To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin
Description: To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
Study: NCT05862506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Mile
Description: The intervention consisted of walking, jogging or running for \~ 15 min (\~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
Study: NCT05439785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental floss/Interdental brush
Description: Initially plaque disclosing tablets were used to disclose plaque and plaque and bleeding scores will be recoded. After mechanical plaque debrided, instructions regarding the allocated interdental device given to the patient along with motivation to continue practicing good oral hygiene. After six weeks patients were recalled for reevaluation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental floss/Interdental brush
Description: Initially plaque disclosing tablets were used to disclose plaque and plaque and bleeding scores will be recoded. After mechanical plaque debrided, instructions regarding the allocated interdental device given to the patient along with motivation to continue practicing good oral hygiene. After six weeks patients were recalled for reevaluation
Study: NCT06174090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary bypass graft surgery video education
Description: It includes information about surgical process and handling issues within the first few days of surgery.
Study: NCT05677685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VISUPRIME
Description: twice daily

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study: NCT04291170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QDASH
Description: completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
Study: NCT05061290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Porridge
Description: Maize porridge containing 54Fe as iron sulfate
Study: NCT04291170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KOOSJR
Description: completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
Study: NCT05030285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.
Study: NCT06043544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe
Description: Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
Study: NCT05061290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Porridge A
Description: Maize porridge counting 58Fe as iron sulfate with ascorbic acid
Study: NCT06530472

Intervention type: OTHER
Intervention: Monitoring
Description: At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.

Intervention type: OTHER
Intervention: Monitoring
Description: At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.

Intervention type: OTHER
Intervention: Monitoring
Description: At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
Study: NCT05061290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Porridge B
Description: Maize porridge containing 57Fe and fortified with Moringa leaf powder as iron source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Porridge C
Description: Maize porridge containing 57Fe and fortified with Boabab fruit powder as iron source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Porridge D
Description: Maize porridge containing 54Fe and fortified with Moringa leaf and Baobab fruit powder as iron source
Study: NCT06006364

Intervention type: OTHER
Intervention: Survey
Description: The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire

Intervention type: OTHER
Intervention: Survey
Description: The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire

Intervention type: OTHER
Intervention: Survey
Description: The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire

Intervention type: OTHER
Intervention: Survey
Description: The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire
Study: NCT06083337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CaRi-Heart device
Description: Open-label treatment with atorvastatin +/- low-dose colchicine medications based on CaRi-Heart algorithm management.
Study: NCT06196801

Intervention type: DRUG
Intervention: Triple-combination therapy
Description: phosphodiesterase 5 inhibitors, endothelin receptor antagonist, and parenteral prostacyclin
Study: NCT05339776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand Lateralization Test
Description: Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
Study: NCT06101225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindRegulation Intervention
Description: The intervention is developed in class for 15 minutes before learning activities, three times per week, for five months - 57 sessions. Six different scripts with socioemotional learning content (based on CASEL framework) for each of the three themes will be applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: The relaxation condition will be developed in the same way as in RegularMente intervention, but without the guided imagery with SEL component. Relaxation exercises applied in class 15 minutes before learning activities, three times per week, for five months - in a total of 57 sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control Group
Description: No Intervention.
Study: NCT06148844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive robot group
Description: Intervention group will receive one day pre-operative preparation intervention applied by researcher. Preparation will be 30-40 minutes long
Study: NCT05918471

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Energy Diet with Liquid Supplementation
Description: The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~1. Consume 4 Optifast 900 packets each day~2. Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~3. Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender.
Study: NCT05781880

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen 100%
Description: NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen 100%
Description: NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)